hotspot -WSS

hotspot

author：knowledge 2025-09-06 03:27:48 - browse：6

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Apple Vision Pro: A first look at health apps on the new VR headset

hotspot

explore

WSS

What we need to know about Arena Bioworks

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

The FDA weighs the risks of candy

Even great ERs can’t make up for American health disparities

ARCH Venture Partners is raising $3 billion for a life sciences fund

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

focus

hotspot

entertainment

In age of alternative facts, a scholarly course on calling out crap

Emergency medicine has repudiated 'excited delirium.' Now what?

Anesthesiologist group: stop taking Ozempic before surgery

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Affirmative action in medical school literally saved lives

Readout Newsletter: What happened with Sarepta's Duchenne data

At least 13 dead in Texas as scorching temps continue

New Ultima Genomics DNA sequencer can read genome for $100

Medicare details structure of new drug price negotiation program

New Ultima Genomics DNA sequencer can read genome for $100

explore

First Opinion Podcast: How to protect health care in times of war

Time to name cancers by genetics, not organ of origin, expert says

New Ultima Genomics DNA sequencer can read genome for $100

Cybersecurity threat forces Lurie Children's to take systems offline

Apple Vision Pro: A first look at health apps on the new VR headset

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

explore

hotspot

explore

hotspot